Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1088 | 1030 | 1163 | 1259 | 1720 | 2856 |
Fund Return | 8.83% | 2.95% | 16.34% | 7.97% | 11.46% | 11.06% |
Place in category | 3904 | 3333 | 3814 | 2179 | 1421 | 461 |
% in Category | 57 | 50 | 63 | 44 | 38 | 21 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Cap Group New Perspective lux C JPY | 13.94B | 9.09 | 3.44 | - | ||
Cap Group NewPerspective lux ZL JPY | 14.48B | 8.83 | 2.84 | 10.22 | ||
Capital Group Global Allocation Fcj | 1.36B | 5.74 | 5.25 | 7.97 | ||
EM Total Opportunities LUX Cj | 610.12M | 2.09 | -1.55 | 2.73 | ||
Cap Group inv CoAmerica lux Z JPY | 443.29M | 10.45 | 9.37 | 10.34 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Wellington Global Research Equity t | 55.55B | 15.42 | 15.19 | 14.57 | ||
MS Global Brands Fund Aj | 21.63B | -0.03 | 2.26 | 8.14 | ||
MFS Global Value ex Japan Fund Q4JP | 96.52M | 18.07 | 17.98 | 12.71 | ||
ValueInvest LUX Global A Disj | 450.73M | 4.83 | 3.74 | 7.64 | ||
ValueInvest LUX Global I Caj | 450.73M | 5.25 | 4.73 | 8.67 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 3.13 | 1,002.6 | -0.44% | |
Broadcom | US11135F1012 | 2.58 | 1,586.66 | -0.34% | |
Microsoft | US5949181045 | 2.37 | 452.85 | +0.15% | |
AstraZeneca | GB0009895292 | 1.99 | 12,328.0 | -1.82% | |
Safran | FR0000073272 | 1.98 | 197.80 | +0.48% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review